TY  - JOUR
AU  - Sadowski, Jerzy
AU  - Bartus, Krzysztof
AU  - Kapelak, Boguslaw
AU  - Rocha-Singh, Krishna J.
AU  - Katholi, Richard E.
AU  - Witkowski, Adam
AU  - Kadziela, Jacek
AU  - Januszewicz, Andrzej
AU  - Prejbisz, Aleksander
AU  - Walton, Anthony S.
AU  - Sievert, Horst
AU  - Id, Dani
AU  - Wunderlich, Nina
AU  - Whitbourn, Robert
AU  - Rump, Lars Christian
AU  - Vonend, Oliver
AU  - Saleh, Andreas
AU  - Thambar, Suku
AU  - Nanra, Ranjit
AU  - Zeller, Thomas
AU  - Erglis, Andrejs
AU  - Sagic, Dragan
AU  - Bošković, Srdjan
AU  - Brachmann, Johannes
AU  - Schmidt, Martin
AU  - Wenzel, Ulrich O.
AU  - Bart, Bradley A.
AU  - Schmieder, Roland E.
AU  - Scheinert, Dierk
AU  - Boergel, Jan
AU  - Straley, Craig
AU  - Symplicity HTN-1 Investigators
PY  - 2011
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/4283
AB  - Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)
T2  - Hypertension
T1  - Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months
VL  - 57
IS  - 5
SP  - 911
EP  - 917
DO  - 10.1161/HYPERTENSIONAHA.110.163014
ER  - 

@article{
author = "Sadowski, Jerzy and Bartus, Krzysztof and Kapelak, Boguslaw and Rocha-Singh, Krishna J. and Katholi, Richard E. and Witkowski, Adam and Kadziela, Jacek and Januszewicz, Andrzej and Prejbisz, Aleksander and Walton, Anthony S. and Sievert, Horst and Id, Dani and Wunderlich, Nina and Whitbourn, Robert and Rump, Lars Christian and Vonend, Oliver and Saleh, Andreas and Thambar, Suku and Nanra, Ranjit and Zeller, Thomas and Erglis, Andrejs and Sagic, Dragan and Bošković, Srdjan and Brachmann, Johannes and Schmidt, Martin and Wenzel, Ulrich O. and Bart, Bradley A. and Schmieder, Roland E. and Scheinert, Dierk and Boergel, Jan and Straley, Craig and Symplicity HTN-1 Investigators",
year = "2011",
abstract = "Renal sympathetic hyperactivity is seminal in the maintenance and progression of hypertension. Catheter-based renal sympathetic denervation has been shown to significantly reduce blood pressure (BP) in patients with hypertension. Durability of effect beyond 1 year using this novel technique has never been reported. A cohort of 45 patients with resistant hypertension (systolic BP GT = 160 mm Hg on GT = 3 antihypertension drugs, including a diuretic) has been originally published. Herein, we report longer-term follow-up data on these and a larger group of similar patients subsequently treated with catheter-based renal denervation in a nonrandomized manner. We treated 153 patients with catheter-based renal sympathetic denervation at 19 centers in Australia, Europe, and the United States. Mean age was 57 +/- 11 years, 39% were women, 31% were diabetic, and 22% had coronary artery disease. Baseline values included mean office BP of 176/98 +/- 17/15 mm Hg, mean of 5 antihypertension medications, and an estimated glomerular filtration rate of 83 +/- 20 mL/min per 1.73 m(2). The median time from first to last radiofrequency energy ablation was 38 minutes. The procedure was without complication in 97% of patients (149 of 153). The 4 acute procedural complications included 3 groin pseudoaneurysms and 1 renal artery dissection, all managed without further sequelae. Postprocedure office BPs were reduced by 20/10, 24/11, 25/11, 23/11, 26/14, and 32/14 mm Hg at 1, 3, 6, 12, 18, and 24 months, respectively. In conclusion, in patients with resistant hypertension, catheter-based renal sympathetic denervation results in a substantial reduction in BP sustained out to GT = 2 years of follow-up, without significant adverse events. (Hypertension. 2011;57:911-917.)",
journal = "Hypertension",
title = "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months",
volume = "57",
number = "5",
pages = "911-917",
doi = "10.1161/HYPERTENSIONAHA.110.163014"
}

Sadowski, J., Bartus, K., Kapelak, B., Rocha-Singh, K. J., Katholi, R. E., Witkowski, A., Kadziela, J., Januszewicz, A., Prejbisz, A., Walton, A. S., Sievert, H., Id, D., Wunderlich, N., Whitbourn, R., Rump, L. C., Vonend, O., Saleh, A., Thambar, S., Nanra, R., Zeller, T., Erglis, A., Sagic, D., Bošković, S., Brachmann, J., Schmidt, M., Wenzel, U. O., Bart, B. A., Schmieder, R. E., Scheinert, D., Boergel, J., Straley, C.,& Symplicity HTN-1 Investigators. (2011). Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension, 57(5), 911-917.
https://doi.org/10.1161/HYPERTENSIONAHA.110.163014

Sadowski J, Bartus K, Kapelak B, Rocha-Singh KJ, Katholi RE, Witkowski A, Kadziela J, Januszewicz A, Prejbisz A, Walton AS, Sievert H, Id D, Wunderlich N, Whitbourn R, Rump LC, Vonend O, Saleh A, Thambar S, Nanra R, Zeller T, Erglis A, Sagic D, Bošković S, Brachmann J, Schmidt M, Wenzel UO, Bart BA, Schmieder RE, Scheinert D, Boergel J, Straley C, Symplicity HTN-1 Investigators. Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months. in Hypertension. 2011;57(5):911-917.
doi:10.1161/HYPERTENSIONAHA.110.163014 .

Sadowski, Jerzy, Bartus, Krzysztof, Kapelak, Boguslaw, Rocha-Singh, Krishna J., Katholi, Richard E., Witkowski, Adam, Kadziela, Jacek, Januszewicz, Andrzej, Prejbisz, Aleksander, Walton, Anthony S., Sievert, Horst, Id, Dani, Wunderlich, Nina, Whitbourn, Robert, Rump, Lars Christian, Vonend, Oliver, Saleh, Andreas, Thambar, Suku, Nanra, Ranjit, Zeller, Thomas, Erglis, Andrejs, Sagic, Dragan, Bošković, Srdjan, Brachmann, Johannes, Schmidt, Martin, Wenzel, Ulrich O., Bart, Bradley A., Schmieder, Roland E., Scheinert, Dierk, Boergel, Jan, Straley, Craig, Symplicity HTN-1 Investigators, "Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension Durability of Blood Pressure Reduction Out to 24 Months" in Hypertension, 57, no. 5 (2011):911-917,
https://doi.org/10.1161/HYPERTENSIONAHA.110.163014 . .